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Abstract
Background: Many women who develop endometrial cancer (EC) or endometrial hyperplasia with atypia are obese
and therefore at high risk of surgical complications. Recently clinical trials have been initiated offering non-surgical
treatment to these women, but not all may agree to participate in such trials. This paper aims to describe the
patient characteristics, and surgical outcomes of women with suspected early stage endometrial cancer and body
mass index (BMI) of 30 or greater, who declined enrolment in the feMMe trial, which offers non-surgical hormonal
treatment, hormonal plus metformin or hormonal plus weight loss as primary treatment.
Methods: Consecutive case series from a tertiary gynaecological oncology unit. Over the course of the first 2 years
of the feMMe trial, 27 patients met the initial eligibility screening, but declined enrolment in the feMMe trial and
opted for upfront surgery. The main surgical outcome measures were type of surgical approach, need for
conversion from laparoscopic to open approach, length of stay in hospital and adverse events.
Results: Patients’ median age was 63 years (range 40 to 86); median BMI was 37.3 kg/m2 (range 30.7 to 54.7);
median medical co-morbidities were six (range 3–10). Of the 26/27 surgeries planned to be undertaken
laparoscopically, 2/26 patients had to be converted (7 %). Overall, the average hospital stay was 4.5 days, and
11/27 (41 %) of the patients developed one or more adverse events grade 2+ rated according to the Common
Toxicity Criteria Version 3.
Conclusions: Adverse surgical outcomes are common in multi-morbid, obese or morbidly obese patients
diagnosed with early stage EC or endometrial hyperplasia with atypia and who have a hysterectomy.
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Background
Obesity is a massive health issue in many countries
around the world and is also the major risk factor for
Endometrial Cancer (EC) [1–4]. It has previously been
reported that obesity causes at least 39 % of cases of EC
[5]. Obesity is also associated with increased risk of
medical co-morbidities (e.g., diabetes, cardiovascular)
[6–8]; the need for intense preoperative assessments;
perioperative complications [9]; conversion from laparo-
scopic to open surgery [10]; intensive postoperative care
[11, 12]; treatment costs [11, 13]; and reduced recurrence-
free survival [9, 14, 15].
While surgical treatment of EC is generally effective, it
does not address the specific needs of the steadily growing
group of morbidly obese and multi-morbid patients as
well as young obese patients still desiring fertility [16, 17].
For these growing groups of patients treatment often
comes at a high personal cost (long hospital stay, pro-
tracted recovery from surgery, high incidence of postoper-
ative complications) and subsequent high healthcare cost.
We previously estimated hospital costs of $12,872 vs
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$25,652 for patients without or with a surgical complica-
tion, respectively [11].
The challenges of pre- and postoperative care for
multi-morbid and morbidly obese EC patients impact on
a variety of resources. Thus, as highlighted by the Royal
College of Obstetricians and Gynaecologists, treatment
for EC needs to be reassessed in this complex and in-
creasingly common situation [18]. The search for treat-
ment alternatives that are safe, effective and less harmful
than surgery is warranted.
Recently, the Gynecologic Cancer InterGroup identi-
fied conservative treatment for fertility sparing purposes
and to treat morbidly obese women as a most pressing
research priority at their EC Clinical Trials Planning
Meeting in the Netherlands [19].
To address this need the feMMe trial was initiated in
2013 [20]. It is an open-label, randomised clinical trial
exploring conservative, non-surgical treatment options
to achieve a pathological complete response in patients
diagnosed with early-stage EC (ANZGOG #1301,
NCT01686126).
The aim of the present study was to describe the safety
and clinical outcomes of consecutive patients who would
have fulfilled the eligibility criteria for the feMMe trial
and who were offered participation in the feMMe trial,
but declined enrolment and opted for hysterectomy at
two institutions instead.
Methods
Approval for this study was received from the Royal
Brisbane & Women’s Hospital Human Research Ethics
Committee (HREC/15/QRBW/113). All patients reported
here have been identified through gynaecological oncology
services at Royal Brisbane and Women’s Hospital and
Greenslopes Private Hospital. These patients would have
been considered potentially eligible to be enrolled in the
feMMe trial.
The feMMe trial is an open label, randomised phase II
trial with three treatment arms and is recruiting patients
at present [20]. The three arms consist of Intrauterine
Progestin (IUP) placed into the uterine cavity (45 pa-
tients); IUP plus Metformin 1000 mg daily (75 patients);
or IUP plus weight loss through Weight Watchers (45
patients). Weight Watchers is a standardised, evidence-
based and formally tested weight loss intervention
including diet, physical activity, social networking and
support via a network of lifestyle centres, one-on-one
support and an online program [21, 22]. It has been
shown to be the most cost-effective among a range of
currently available weight loss programs [22].
In this phase II trial randomisation aims to eliminate
selection bias rather than allow a formal comparison of
groups. Trial methodology, in-/exclusion criteria, random-
isation /stratification and study assessments were published
recently [20]. Human Research and Ethics Committee and
site-specific approvals are underway in various Australian
States but only sites in the state of Queensland are fully ap-
proved and enrolling at present. All patients are followed
for 6 months and a central pathology review will be con-
ducted once all patients are enrolled.
Eligibility criteria: Only patients with histologically
confirmed innocuous EC or endometrial hyperplasia
with atypia, Body Mass Index (BMI) >30 kg/m2 who
wish to retain fertility or who suffer from medical impair-
ments and are considered suboptimal candidates for hys-
terectomy are eligible [20].
Patients are excluded from enrolment if they had a
histological type other than endometrioid adenocarcinoma
of the endometrium, clinically advanced disease, involve-
ment of the uterine cervix or enlarged retroperitoneal
lymph nodes.
To be eligible for this study, patients had to have a CT
scan of the abdomen and pelvis as well as imaging (CT
or X-Ray to the chest) suggesting the absence of extra-
uterine disease. Patients are also only considered eligible
if their baseline serum CA-125 reading was 30 U/ml or
less.
Patients who agree to proceed with enrolment into the
feMMe trial receive a pelvic MRI to ensure that the
depth of invasion is not greater than 50 % of myome-
trium and to re-confirm the absence of extrauterine dis-
semination. Patients who decline participation in feMMe
(including the patients reported herein) however do not
receive an MRI as it is not part of the standard imaging
workup in our institutions.
In addition to the established criteria for low-risk disease
(CT and MRI scan showing the absence of extrauterine dis-
ease, FIGO grade = 1) we offer enrolment only to patients
with serum CA125 of 30 U/ml or less [23]. Considering
the strict criteria above, we expect that the risk of enrolling
patients with advanced or aggressive disease is minimal.
All patients reported here did not qualify for feMMe
because they preferred hysterectomy and as a conse-
quence declined enrolment into the feMMe trial. Hence,
following standard protocols, a pelvic MRI was not
offered (as has been explained above).
In all 27 patients, pre-existing medical co-morbidities
were recorded as well as any intra- or post-operative
Adverse Events (AEs) up to 30 days post-operatively. We
coded AEs according to the post-operative Common
Toxicity Criteria (CTC) Version 3 and report any AEs
grade 2+ (moderate to severe AEs). Analyses were re-
stricted to women who completed 30 days of follow-up
after surgery.
Results
The clinical outcomes of 27 patients who fulfilled the eli-
gibility criteria but declined participation in the feMMe
Obermair et al. Gynecologic Oncology Research and Practice  (2016) 3:1 Page 2 of 6
trial and have chosen primary surgical treatment instead
are reported here.
Patients’ median age was 63 years (range 40 to 86 years)
and the median BMI was 37.3 kg/m2 (range 30.7 to
54.7 kg/m2), median ASA was 3 (range 2–3). At baseline
a total of 167 medical co-morbidities were recorded
among the 27 patients including hypertension, hyperlipid-
emia, hypercholesterolemia, diabetes, obstructive sleep ap-
noea, fatty liver and many other lifestyle-related ailments.
Twenty-six patients had a total laparoscopic procedure
of which two patients (7 %) had to be converted to a
laparotomy. One patient required an abdominal hyster-
ectomy through a midline incision (Table 1).
The reasons for conversion to open surgery in two
patients included an inadvertent gastrotomy through a
trocar at primary port entry, which required primary
surgical closure. The second patient sustained an enter-
otomy to the small bowel during adhesiolysis. The
Table 1 Patient characteristics
Patient # Age
(years)
D&C
histology
BMI Surgical
approach
Node
dissection
LOS Stage FIGO
grade
Depth of
invasion (%)
Intra-, Postoperative complications
1 40 EHA 31.0 TLH 0 2 1a 1 15
2 56 G1 EAC 49.2 TLH 0 1 1a 1 0 Post-operative bleeding
3 62 G1 EAC 35.1 TLH 0 2 1a 2 11
4 69 G1 EAC 54.7 TLH 0 2 1a 2 38 Vault haematoma, abdominal
cramping, urinary frequency
5 75 G1 EAC 39.6 TLH 0 2 1a 1 0
6 65 G1 EAC 40.9 TLH 0 2 1b 2 60
7 56 G1 EAC 42.7 TLH 0 5 1a 1 0
8 74 G1 EAC 46.8 TLH 0 1 1b 2 52
9 73 G1 EAC 44.8 TLH 0 8 2 2 18 Post-operative bleeding, anaemia,
retroperitoneal haematoma, rise in
Troponin
10 68 EHA 35.4 TLH 1 2 1b 2 60
11 75 G1 EAC 38.9 TLH converted
to TAH
0 14 1b 2 57 Unplanned gastrostomy,
unplanned stay in ICU
12 69 EHA 45.5 TLH 0 2 1a 0
13 67 G1 EAC 32.5 TLH 0 3 1a 2 8 Vault haematoma, hypokalaemia,
sinus tachycardia
14 57 G1 EAC 30.7 TLH 0 2 1a 1 50 Vault haematoma, pain
15 73 G1 EAC 34.3 TLH 0 5 1a 1 10
16 69 EHA 29.4 TLH 0 2 1a 1 0 Vault haematoma, hypotension,
hypokalaemia
17 68 G1 EAC 43.9 TLH 0 2 1a 2 45
18 78 G1 EAC 32.0 TLH 0 2 1a 1 45
19 63 EHA 33.5 TLH 0 2 0 0 Hypertension
20 66 EHA 40.6 TLH 0 2 1a 1 1 Atrial fibrillation
21 60 EHA 37.1 TLH 0 7 1a 1 37
22 70 EHA 43.1 TLH 0 5 1b 2 75 Chest infection, wound dehiscence,
vault haematoma, pain
23 72 G1 EAC 42.7 TLH 1 3 3b 1 100
24 50 EHA 35.6 TLH 0 9 1a 1 39 Fluid overload, pulmonary oedema
25 55 G1 EAC 33.3 TAH 0 4 2 1 7
26 73 G1 EAC 47.0 TLH 0 2 1a1 1 0
27 86 G1 EAC 43.6 TLH converted
to TAH
1 28 1a 1 31 Unplanned enterotomy, wound
infection, Atrial fibrillation,
renal failure
Abbreviations: BMI body mass index, EAC endometriod adencocarcinoma, EHA endometrial hyperplasia with atypia, TLH total laparoscopic hysterectomy, TAH total
abdominal hysterectomy, LOS length of stay, FIGO the international federation of gynecology and obstetrics
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adhesions could not be dissected from the anterior
abdominal wall laparoscopically. The enterotomy was
recognised at surgery and the operation was completed
through open surgery. The median percentage of inva-
sion into the endometrium was 31 % (range 0–100 %).
The average postoperative hospital stay was 4.5 days
(median 2 days), ranging from 1 to 28 days. The patient
with a 28-day hospital stay was a patient with a body
mass index of 43.6 kg/m2 who required conversion from
laparoscopic to open surgery. She developed a wound
infection (limited to the subcutaneous adipose tissue),
atrial fibrillation resulting in a stay at the Cardiac Care
Unit followed by acute renal failure. The patient was dis-
charged into rehab on day 28 post surgery.
Within 30 days from surgery, 12 patients developed at
total of 30 AEs. One of 27 patients developed an AE
CTC grade 1 and 11/12 patients developed one or more
AEs CTC grade 2+ (41 %). All but 5 AEs were surgery
related (Table 1).
Nine patients were enrolled to treat endometrial
hyperplasia with atypia based on a pre-hysterectomy
endometrial biopsy or curette and 18 of 27 patients had
surgery for histologically proven endometrioid endomet-
rial adenocarcinoma on endometrial biopsy or curette.
Of those nine patients who were treated for endomet-
rial hyperplasia with atypia, seven patients were found to
have endometrial adenocarcinoma in the final histopath-
ology specimen of the uterus.
In patients with the final histopathological outcomes
confirming endometrial adenocarcinoma, all patients
were diagnosed with endometrioid cell type. In those
patients FIGO grade was grade 1 in 14/25 patients and
grade 2 in 10/25 patients. In one patient there was no
residual disease at hysterectomy. The depth of invasion
was limited to inner half in all but five patients.
Two patients had extension of disease into the endo-
cervix (stage 2) and one patient had full thickness
myomterial invasion of a grade 1 adenocarcinoma and
focal involvement of a fallopian tube (FIGO stage 3b).
Discussion
Main findings
Adverse surgical outcomes are common in multi-morbid
and morbidly obese patients diagnosed with early stage
EC who have a hysterectomy. Obesity is an independent
risk factor for AEs, regardless of the surgical approach
[12]. Obese women will have a higher risk of conversion
to open surgery [10] and their risk of surgical AEs is
higher [24].
For comparison we quote data from the prospective
randomised and multi-institutional LACE trial below
[12, 25]. The LACE trial compared open with laparo-
scopic surgery for early stage EC or endometrial hyper-
plasia with atypia. It was an international trial but the
vast majority of patients were treated in Australian
institutions.
In the case series reported here, all but one operations
were planned to be performed laparoscopically; two of
the 27 patients required a conversion from laparoscopy
to laparotomy (7 %) and one patient required a primary
laparotomy, implying that 10 % of patients required a
laparotomy to accomplish the surgical task of a hysterec-
tomy. By contrast, the conversion rate from laparoscopic
to open in the prospective randomised and multi-
institutional LACE trial was only 3.8 %, most likely due
to omitting the requirements for a comprehensive pelvic
and aortic retroperitoneal node dissection in these pa-
tients and a smaller proportion of patients with a BMI
of 30 or greater.
By contrast, pelvic and aortic lymph node dissection
was mandatory in the LAP-2 trial corresponding to a
25.8 % conversion rate. Patients with a high BMI had an
up to 60 % risk of conversion to open surgery [24].
In the context of morbidly obese and multi-morbid
patients we typically aim to minimise the risk of conver-
sion, which may attract further intraoperative and post-
operative morbidity. In those instances patients’ adjuvant
treatment may be guided by their general medical health
and histopathological features available from the primary
tumour. At present only low-level evidence is available
on the feasibility and safety of robotic surgery in mor-
bidly obese patients requiring a retroperitoneal node dis-
section. Deaths due to complications of robotic surgery
have also been reported [26].
In this sample, the mean length of hospital stay (LOS)
was 4.5 days. Length of stay was largely associated with
the development of postoperative complications. However,
in some patients an uneventful postoperative recovery still
required a longer than expected LOS due to slow recov-
ery. In the LACE trial, reflecting the Australian health care
situation the LOS was 2.4 days for patients assigned to
have a laparoscopic hysterectomy and 5 days for patients
who were randomised to have a laparotomy.
In this series of patients the per-patient incidence of
surgical AE’s CTC grade 2+ was high at 41 %.
Strength and limitations
Innovatively this case series details the outcomes of
patients who were offered enrolment in a non-surgical
clinical trial, but preferred surgery. These results again
highlight the increased risk of obese patients to develop
complications as previously shown in other international
series. This group of morbidly obese and multi-morbid
patients carries a high risk of conversion to laparotomy,
a longer hospital stay and a three to four times higher
risk of surgical AEs compared to previous series with a
wider range of BMI. LOS and AEs are significant contribu-
tors to health care costs and funders of health care services
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must therefore expect high costs among obese patients
treated surgically for EC [13]. Limitations of this study
include the non-random assignment to surgery, which was
based on patients’ preference, as well as the relatively small
number of patients available for data collection.
Conclusions
While hysterectomy for EC offers excellent survival
outcomes, it also comes at a price: slow recovery from
surgery, surgical AEs, loss of fertility, financial and soci-
etal treatment costs [27, 28].
Importantly these results indicate that current risk es-
timations do not take populations at high surgical risk
(e.g. obese and multi-morbid patients) into sufficiently
account. Thus, the efficacy of treatment alternatives
need to be assessed in the complex and increasingly
common situation of obesity and EC or endometrial
hyperplasia with atypia [18]. We envisage that for obese
and multimorbid patients less invasive treatments will
achieve equivalent survival outcomes at a lower personal
and financial cost to patients and society [13].
Historically intracavitary brachytherapy has been used
to treat patients at advanced age and severe medical ill-
nesses and with the advent of IMRT [29], radiotherapy
may be well positioned to be evaluated in clinical trials
as an alternative to major surgery.
By contrast, others units currently investigate the ef-
fectiveness of a levonorgestrel containing intrauterine
device for the treatment of endometrial cancer. The
feMMe trial (ANZGOG #1301, NCT01686126) is an
international, phase II, 3-arm randomised clinical trial
exploring conservative, non-surgical treatment options
to achieve a pathological complete response in early-
stage endometrial cancer patients who are suboptimal
candidates for hysterectomy [20].
In addition to the eligibility criteria for this case series,
patients have to have an MRI of the pelvis to determine
the depth of myometrial invasion. In the context of the
results reported here this is well warranted, and the
pelvic MRI will also be critical to exclude involvement of
the cervix and/or adnexae.
The trial is recruiting at present (Fig. 1 shows the
recruitment chart) and also includes a molecular compo-
nent investigating the mechanisms of change associated
with response or non-response to feMMe intervention
(tumour polymorphisms; molecular phenotype of tu-
mours; circulating cytokines, such as adipokines, hor-
mones and growth factors). Phase II results are expected
for 2017, and early discussion about the optimal Phase
III trial design to follow have been initiated in 2015.
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